Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Non-Current AssetsPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Crescent Biopharma (CBIO) Current Assets (2016 - 2025)

Crescent Biopharma (CBIO) has disclosed Current Assets for 11 consecutive years, with $236.7 million as the latest value for Q4 2025.

  • Quarterly Current Assets changed N/A to $236.7 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $236.7 million through Dec 2025, changed N/A year-over-year, with the annual reading at $236.7 million for FY2025, N/A changed from the prior year.
  • Current Assets for Q4 2025 was $236.7 million at Crescent Biopharma, up from $134.6 million in the prior quarter.
  • The five-year high for Current Assets was $236.7 million in Q4 2025, with the low at $6.0 million in Q1 2025.
  • Average Current Assets over 5 years is $80.0 million, with a median of $61.3 million recorded in 2022.
  • Peak annual rise in Current Assets hit 760.06% in 2025, while the deepest fall reached 81.99% in 2025.
  • Over 5 years, Current Assets stood at $90.8 million in 2021, then crashed by 44.14% to $50.7 million in 2022, then dropped by 13.65% to $43.8 million in 2023, then tumbled by 64.27% to $15.6 million in 2024, then surged by 1412.58% to $236.7 million in 2025.
  • According to Business Quant data, Current Assets over the past three periods came in at $236.7 million, $134.6 million, and $154.2 million for Q4 2025, Q3 2025, and Q2 2025 respectively.